Preventing readmission after TAVI: rationale and context

Transcatheter valve replacement has transformed care for severe aortic stenosis, expanding treatment to older and higher risk patients. As utilization has grown, attention has shifted from in-hospital metrics to post-discharge trajectories, including readmission within the first weeks after the index procedure. These rehospitalizations are clinically meaningful and often preventable, intersecting cardiovascular, procedural, and geriatric domains. They also strain capacity and budget in systems facing rising case volumes and tighter staffing. In this context, intensified follow-up strategies offer a testable way to reduce avoidable events while maintaining safety.

Reasons for unplanned return to acute care commonly include heart failure decompensation, conduction disturbances or bradyarrhythmias, access-site or bleeding complications, infection, and renal deterioration. Medication transitions and new device care requirements can challenge self-management. Recovery may be uneven among patients with multimorbidity and baseline functional impairment. Early, structured contact after discharge could surface actionable symptoms before they escalate. It also creates a platform for targeted education, medication titration, and coaching for successful recovery at home.

Clinical drivers of early readmission

Procedural factors such as vascular access management, valve positioning, and conduction system injury contribute to early adverse events that can precipitate an unplanned hospitalization. On the medical side, volume status and diuretic regimens often need adjustment as afterload abruptly falls, potentially unmasking right-sided congestion or precipitating acute kidney injury. Residual or paravalvular regurgitation may add hemodynamic stress. Cognitive fluctuations and delirium can impair adherence or trigger safety concerns, particularly in patients with baseline vulnerability.

Cardiac comorbidities are frequent and interact with recovery. A prior history of heart failure or atrial fibrillation raises the likelihood of recurrent dyspnea or fluid retention, and anticoagulation management can be complex when bleeding risk is higher immediately post-procedure. Noncardiac contributors matter too, including anemia, malnutrition, and social factors that affect access to care. Mapping these drivers clarifies the targets for a follow-up pathway that can preempt deterioration. It also aids in prioritizing contacts and the content of each touchpoint.

Transitional care opportunities

Transitions from hospital to home concentrate risk and reveal actionable gaps. A standardized approach to transitional care after TAVI can align the team around several priorities. These include early detection of fluid shifts, device or access-site issues, and conduction-related symptoms. They also include careful medication reconciliation and reinforcement of anticoagulation plans, which are central to preventing thromboembolic and bleeding complications. Embedding reminders and clear escalation pathways supports patients and caregivers in navigating the first few weeks.

Digital tools can extend the reach of programs beyond in-person checks. Select measures such as daily weights, blood pressure, heart rate, and symptom journals are feasible through simple home devices. When paired with a triage protocol, remote monitoring can flag concerning patterns. Video or telephone touchpoints via telemedicine can verify wound healing, assess dyspnea and edema, and adjust therapy promptly. A hybrid strategy that combines early clinic reviews with virtual follow-ups is attractive for older adults, provided accessibility and usability are addressed.

PREMISS randomized feasibility design and conduct

PREMISS was a parallel-group randomized controlled trial designed to assess whether an intensified follow-up strategy could be delivered consistently after TAVI and to characterize early clinical outcomes. The protocol and feasibility results are available via PubMed. Participants undergoing transcatheter valve implantation were randomized to a structured, multi-touch follow-up pathway or to usual post-discharge care per local standards. The aim was not only to explore signals on readmission but also to quantify operational parameters required for a larger, adequately powered evaluation. By prospectively capturing adherence and contact fidelity, the investigators situate their findings in the practical realities of program deployment.

Typical inclusion in this setting spans older adults with severe symptomatic aortic stenosis treated via transfemoral access, with exclusions that might include inability to engage in follow-up contacts or competing indications for prolonged hospitalization. Randomization ideally balances baseline risks, including comorbidity burden and social support. Although the single trial may not capture all practice environments, it tests a reproducible care sequence that many centers could implement. This design helps parse whether it is feasible to standardize and scale enhanced follow-up across clinical workflows. It also generates structure for auditing process measures alongside outcomes.

Intervention components

The intensified pathway typically layers early, scheduled contacts onto standard care. Core elements include a nurse-led phone call within days of discharge to review symptoms, device-site care, and medications, followed by a clinic or virtual check to assess hemodynamics and access sites. Additional touchpoints over the first month provide opportunities to titrate diuretics or rate control, reinforce anticoagulation plans, and revisit red flags prompting escalation. Incorporation of simple home measurements enhances monitoring, with thresholds guiding rapid feedback and clinical action. The program may also solicit patient-reported outcomes to inform individualized coaching.

Education and navigation are essential to the model. Clear, written action plans help patients recognize when worsening dyspnea, dizziness, syncope, or bleeding merits immediate contact. A dedicated line or inbox with same-day response reinforces accessibility. Caregivers receive guidance on assisting with daily weights, inspection of the access site, and medication organization. Social work or pharmacy involvement can stabilize access to prescriptions and supplies. Together, these components seek to reduce uncertainty during recovery and to intercept deterioration before it requires acute care.

Feasibility endpoints and analysis

Feasibility trials emphasize process and operational metrics. PREMISS prospectively reported parameters such as screening and consent rates, randomization efficiency, protocol fidelity, and completion of scheduled contacts. It also characterized acceptability and adherence to the follow-up schedule from both patient and provider perspectives. Safety signals, resource demands, and any unintended consequences were recorded to refine future workflows. Feasibility outcomes, rather than definitive clinical effects, are the principal lens through which these results should be interpreted. Analyses are generally descriptive, informing the assumptions and thresholds required for a larger phase.

Target outcomes for a subsequent definitive trial can be calibrated using these feasibility data. These include which readmission definitions are most reliable, the optimal time horizon for primary analysis, and whether to incorporate emergency department visits or urgent clinic encounters as part of a composite. The trial also clarifies which process measures are most sensitive to change, such as time to first contact after discharge or proportion of high-risk patients receiving an advanced review. Finally, the feasibility experience informs sample size assumptions by showing variance and event rates in the enrolled population, which are crucial for power calculations.

Early clinical outcomes and safety observations

Alongside process metrics, PREMISS collected early clinical outcomes including unplanned readmissions, emergency visits, and safety events such as bleeding, vascular complications, conduction disturbances, and mortality. The randomized framework strengthens interpretation by reducing allocation bias in early event comparisons. Although feasibility trials are not powered for definitive effect estimates, directional patterns can identify promising targets and help refine inclusion criteria. Any observed differences in early events should be viewed as hypothesis-generating and a prompt for careful design of a confirmatory trial. Safety observations also guide which monitoring thresholds and escalation triggers are most appropriate.

It is equally important to identify neutral or negative signals. Intensified follow-up can inadvertently increase low-value utilization if thresholds are set too conservatively or if contact overload creates confusion. Conversely, too few touchpoints may fail to capture evolving symptoms. The feasibility window allows teams to balance sensitivity and specificity of alerts, test documentation burden, and assess clinician workload. These operational findings shape a pathway that is both patient-centered and sustainable inside contemporary cardiology practices.

Operational lessons for implementation

Program delivery hinges on staffing, scheduling, and data flows. Nurse coordinators or advanced practice providers often anchor the contact schedule, with clear delegation for medication adjustments under protocol. Template-driven documentation in the electronic record can streamline each touchpoint and cue standardized assessments, while dashboards summarize pending tasks and vitals. Automated reminders reduce missed appointments and support timely follow-up. A defined escalation ladder ensures that concerning findings translate into same-day decisions by the interventional or structural heart team.

Technology should be matched to patient capability. Not all older adults will adopt smartphone apps or connected devices, so options spanning basic phone calls to Bluetooth-enabled scales are needed. Training and support for caregivers widen participation. Workflow integration with the catheterization laboratory, inpatient teams, and outpatient clinics prevents handoff failures. Finally, governance for data privacy and security is essential, especially when virtual visits and home data streams are used to inform clinical choices. These elements collectively determine the real-world viability of an intensified post-TAVI pathway.

Implications for care pathways and future research

The feasibility insights from PREMISS provide a practical blueprint for clinical teams aiming to standardize post-TAVI follow-up. They also supply the parameters needed to design a definitive trial that evaluates the impact on unplanned readmissions, patient-centered outcomes, and costs. For health systems, the question is as much about how to deliver consistent, high-quality follow-up as it is about whether such programs improve early outcomes. The randomized experience helps address both by clarifying operational requirements and the measurable results worth pursuing. It also identifies the points of variation that most influence performance.

Targeting those at highest risk

Resource intensity argues for prioritized follow-up among patients at greatest likelihood of early deterioration. A practical approach blends clinical variables with contextual factors. Candidates for intensified monitoring often include individuals with significant conduction disease, severe right ventricular dysfunction, or marked diuretic needs at discharge. Measures of frailty and functional status add prognostic value beyond traditional comorbidity indexes. Incorporating simple biomarkers or echocardiographic features might refine this further, as could social factors such as living alone or limited transportation.

Centers can develop a simple risk stratification tool to triage patients into standard versus intensified pathways. In many programs, this can be as pragmatic as a checklist scored at discharge. The tool should be easy to use and validated locally, then iteratively improved as performance data accumulate. Randomized feasibility data inform the cut points at which added touchpoints appear most useful. Aligning pathway intensity to risk makes the best use of limited personnel and reduces unnecessary contacts in lower-risk patients.

Integration with remote monitoring and telemedicine

Hybrid models that pair clinic visits with virtual contacts are now standard in many structural heart programs. The feasibility experience highlights which measures are practicable for the average TAVI recipient and which escalation rules drive timely action without excessive noise. For example, daily weights and symptom checks may offer the best yield-to-effort ratio, with blood pressure and pulse as complementary signals. Secure messaging can support medication titration, while scheduled video visits enable visual assessment of edema and access-site healing. Building this around a vetted communication platform ensures reliability.

Equity and usability merit attention. Alternatives should be available for patients who cannot or prefer not to use digital tools, including language-concordant phone calls and printed materials. Programs should monitor participation to avoid widening disparities in care. Training modules for staff and caregivers improve consistency and confidence in virtual care. Finally, quality metrics for hybrid follow-up, such as time to first contact and completion rate of scheduled touchpoints, provide a shared scorecard. These measures can be incorporated into continuous improvement cycles and external reporting when appropriate.

Designing definitive trials

With feasibility established, the next step is a fully powered evaluation that specifies a primary endpoint, time horizon, and analytic framework aligned to clinical priorities. A common choice is all-cause 30-day readmission, though longer windows may capture delayed complications. Composite endpoints that include urgent clinic or emergency visits need careful justification to avoid diluting interpretability. Stratification by baseline risk and prespecified subgroup analyses can reveal heterogeneity of treatment effect. Data on resource use and program costs enable cost-effectiveness analyses that inform payers and policy.

Trial conduct should preserve the pragmatic features that make results generalizable. Broad inclusion criteria, minimal exclusions, and straightforward workflows are essential. To reduce contamination, usual care must be clearly defined and audited, recognizing that standard practice evolves. Processes to maintain protocol adherence in the intervention arm should be explicit and monitorable. Prospective collection of both process and outcome measures ensures that any effect can be traced back to concrete program features, aiding scalability and reproducibility across centers.

Ultimately, the goal is a standardized, patient-centered post-TAVI pathway that demonstrably reduces unplanned utilization without compromising safety. Feasibility results such as those reported in PREMISS help identify what is deliverable, acceptable, and measurable. They sharpen the design of confirmatory trials and support teams seeking to implement hybrid follow-up now while awaiting definitive evidence. By focusing on operational fidelity and clinically meaningful outcomes, the field can move toward reliable, scalable models of recovery support after valve intervention. The next steps include multicenter testing, transparent reporting, and integration with broader cardiac care transitions.